Company intelligence / Profile preview

Confluence Life Sciences

St. Louis, Missouri, United Statesconfluencediscovery.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Confluence Life Sciences developed a pipeline of small molecule kinase inhibitors targeting cancer, chronic inflammation, and autoimmune disorders. Their KINect platform enabled the discovery of novel compounds with improved selectivity. The company was acquired by Aclaris Therapeutics in 2017; some programs advanced to clinical stages before integration into the parent company's portfolio

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CDD-450

Pre-clinical

Indications: Psoriatic arthritis, Inflammatory bowel disease, Rheumatoid arthritis

Partnerships

Not specifically disclosed; value derived from outlicensing/partnering at milestone events with pharma/biotech companies

Beyond the preview

Go deeper on Confluence Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Confluence Life Sciences.

Explore the full profile